Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
ASH 2022
It was a pleasure to speak with Gail Roboz of @WeillCornell at #ASH25 to hear about her AML highlights from this year's meeting. 😊🩸
Click here to watch the interview:
👉 👈
#AMLsm #Leusm #Leukemia #HemOnc @ASH_hematology
AML highlights from ASH 2025: menin inhibitor combinations, MRD, and real-world data
Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, shares her highlights in acute myeloid leukemia (AML) f...
ow.ly
🚨Earlier use of cilta-cel in #myeloma in the CARTITUDE-4 trial is associated with better immune fitness & stronger immune effects!
Samir Parekh of @IcahnMountSinai presented this hot abstract at #ASH25, and you can hear all about it in this interview:
🎥…
Time to reveal our Top 6 most-viewed interviews of the year! 🎥🩸
1) The evolving treatment landscape for patients with #PolycythemiaVera - @MKremyanskaya
2) Dr Jason Westin discusses the ALPHA3 trial from ASCO 2025 - @Lymphoma_Doc
3) Outcomes with CAR-T therapy in autoimmune…
As the year comes to a close, we're looking back on our Top 10 most viewed video interviews of 2025, starting with 7th-10th place! 🎥🩸
7) Updates in the management of CMML: a case-based presentation - Daniel Wiseman (@OfficialUoM)
8) In vivo CAR T-cell therapy: benefits and…
In an interview from #ASH25, @Dr_AmerZeidan (@Yale) shares insights from a secondary analysis of the IMerge trial, which identified a correlation between treatment-emergent cytopenias and clinical response in patients with LR-MDS receiving imetelstat.
Watch here: 👉…
ASH 2022
It was a pleasure to speak with Gail Roboz of @WeillCornell at #ASH25 to hear about her AML highlights from this year's meeting. 😊🩸
Click here to watch the interview:
👉 👈
#AMLsm #Leusm #Leukemia #HemOnc @ASH_hematology
AML highlights from ASH 2025: menin inhibitor combinations, MRD, and real-world data
Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, shares her highlights in acute myeloid leukemia (AML) f...
ow.ly
🚨Earlier use of cilta-cel in #myeloma in the CARTITUDE-4 trial is associated with better immune fitness & stronger immune effects!
Samir Parekh of @IcahnMountSinai presented this hot abstract at #ASH25, and you can hear all about it in this interview:
🎥…
Time to reveal our Top 6 most-viewed interviews of the year! 🎥🩸
1) The evolving treatment landscape for patients with #PolycythemiaVera - @MKremyanskaya
2) Dr Jason Westin discusses the ALPHA3 trial from ASCO 2025 - @Lymphoma_Doc
3) Outcomes with CAR-T therapy in autoimmune…
As the year comes to a close, we're looking back on our Top 10 most viewed video interviews of 2025, starting with 7th-10th place! 🎥🩸
7) Updates in the management of CMML: a case-based presentation - Daniel Wiseman (@OfficialUoM)
8) In vivo CAR T-cell therapy: benefits and…
In an interview from #ASH25, @Dr_AmerZeidan (@Yale) shares insights from a secondary analysis of the IMerge trial, which identified a correlation between treatment-emergent cytopenias and clinical response in patients with LR-MDS receiving imetelstat.
Watch here: 👉…
